These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24114327)

  • 1. Interleukin-32β stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway.
    Park JS; Choi SY; Lee JH; Lee M; Nam ES; Jeong AL; Lee S; Han S; Lee MS; Lim JS; Yoon DY; Kwon Y; Yang Y
    Cell Oncol (Dordr); 2013 Dec; 36(6):493-503. PubMed ID: 24114327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals.
    Yun HM; Oh JH; Shim JH; Ban JO; Park KR; Kim JH; Lee DH; Kang JW; Park YH; Yu D; Kim Y; Han SB; Yoon DY; Hong JT
    Cell Death Dis; 2013 May; 4(5):e640. PubMed ID: 23703385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin.
    Luo M; Hou L; Li J; Shao S; Huang S; Meng D; Liu L; Feng L; Xia P; Qin T; Zhao X
    Cancer Lett; 2016 Apr; 373(1):1-11. PubMed ID: 26805761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-induced IL-32β increases glycolysis in breast cancer cells.
    Park JS; Lee S; Jeong AL; Han S; Ka HI; Lim JS; Lee MS; Yoon DY; Lee JH; Yang Y
    Cancer Lett; 2015 Jan; 356(2 Pt B):800-8. PubMed ID: 25449783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-32θ inhibits stemness and epithelial-mesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer.
    Bak Y; Kwon T; Bak IS; Hong J; Yu DY; Yoon DY
    Oncotarget; 2016 Feb; 7(6):7307-17. PubMed ID: 26824417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration.
    Sloot YJE; Rabold K; Ulas T; De Graaf DM; Heinhuis B; Händler K; Schultze JL; Netea MG; Smit JWA; Joosten LAB; Netea-Maier RT
    Cell Oncol (Dordr); 2019 Oct; 42(5):691-703. PubMed ID: 31201646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells.
    Wu YS; Chung I; Wong WF; Masamune A; Sim MS; Looi CY
    Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):296-306. PubMed ID: 27750041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells.
    Cascio S; D'Andrea A; Ferla R; Surmacz E; Gulotta E; Amodeo V; Bazan V; Gebbia N; Russo A
    J Cell Physiol; 2010 Jul; 224(1):242-9. PubMed ID: 20232316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner.
    Shao S; Zhao X; Zhang X; Luo M; Zuo X; Huang S; Wang Y; Gu S; Zhao X
    Mol Cancer; 2015 Feb; 14(1):28. PubMed ID: 25645291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition.
    Liu H; Ren G; Wang T; Chen Y; Gong C; Bai Y; Wang B; Qi H; Shen J; Zhu L; Qian C; Lai M; Shao J
    Carcinogenesis; 2015 Apr; 36(4):459-68. PubMed ID: 25750173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
    Esparza-López J; Alvarado-Muñoz JF; Escobar-Arriaga E; Ulloa-Aguirre A; de Jesús Ibarra-Sánchez M
    BMC Cancer; 2019 Jul; 19(1):728. PubMed ID: 31337349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects and mechanisms of blockage of STAT3 signaling pathway on IL-6 inducing EMT in human pancreatic cancer cells in vitro.
    Huang C; Yang G; Jiang T; Zhu G; Li H; Qiu Z
    Neoplasma; 2011; 58(5):396-405. PubMed ID: 21744993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT3 can be activated through paracrine signaling in breast epithelial cells.
    Lieblein JC; Ball S; Hutzen B; Sasser AK; Lin HJ; Huang TH; Hall BM; Lin J
    BMC Cancer; 2008 Oct; 8():302. PubMed ID: 18939993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-22 promotes development of malignant lesions in a mouse model of spontaneous breast cancer.
    Katara GK; Kulshrestha A; Schneiderman S; Riehl V; Ibrahim S; Beaman KD
    Mol Oncol; 2020 Jan; 14(1):211-224. PubMed ID: 31725949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GALNT14 mediates tumor invasion and migration in breast cancer cell MCF-7.
    Huanna T; Tao Z; Xiangfei W; Longfei A; Yuanyuan X; Jianhua W; Cuifang Z; Manjing J; Wenjing C; Shaochuan Q; Feifei X; Naikang L; Jinchao Z; Chen W
    Mol Carcinog; 2015 Oct; 54(10):1159-71. PubMed ID: 24962947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-32θ inhibits tumor-promoting effects of macrophage-secreted CCL18 in breast cancer.
    Pham TH; Bak Y; Kwon T; Kwon SB; Oh JW; Park JH; Choi YK; Hong JT; Yoon DY
    Cell Commun Signal; 2019 May; 17(1):53. PubMed ID: 31126309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverse and divergent functions of IL-32β and IL-32γ isoforms in the regulation of malignant pleural mesothelioma cell growth and the production of VEGF-A and CXCL8.
    Numasaki M; Ito K; Takagi K; Nagashima K; Notsuda H; Ogino H; Ando R; Tomioka Y; Suzuki T; Okada Y; Nishioka Y; Unno M
    Cell Immunol; 2023 Jan; 383():104652. PubMed ID: 36516653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PMA treated THP-1-derived-IL-6 promotes EMT of SW48 through STAT3/ERK-dependent activation of Wnt/β-catenin signaling pathway.
    Gao S; Hu J; Wu X; Liang Z
    Biomed Pharmacother; 2018 Dec; 108():618-624. PubMed ID: 30243096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
    Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
    Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.
    Cui B; Zhang S; Chen L; Yu J; Widhopf GF; Fecteau JF; Rassenti LZ; Kipps TJ
    Cancer Res; 2013 Jun; 73(12):3649-60. PubMed ID: 23771907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.